Hexarelin is a synthetic growth-hormone secretagogue hexapeptide designed for ghrelin-receptor activation and growth-hormone secretagogue activity in receptor and pituitary research models. Preclinical studies evaluate its potent signaling pathways, receptor affinity, and functional dynamics in laboratory settings. All PX1 Research compounds are strictly intended for in vitro and laboratory research use only.
Hexarelin is a synthetic growth-hormone secretagogue hexapeptide designed for ghrelin-receptor activation and growth-hormone secretagogue activity in receptor and pituitary research models. Preclinical studies evaluate its potent signaling pathways, receptor affinity, and functional dynamics in laboratory settings. All PX1 Research compounds are strictly intended for in vitro and laboratory research use only.
Hexarelin (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) family. Structurally derived from GHRP-6, Hexarelin incorporates specific D-amino acid substitutions engineered to enhance chemical stability against enzymatic cleavage and increase binding affinity at target receptor sites. Unlike endogenous peptide ligands, Hexarelin maintains a compact hexapeptide chain that resists rapid degradation in aqueous physiological buffers used during bench assays.
In chemical literature, Hexarelin is recognized as one of the most potent synthetic agonists within the GHS class. It does not possess the n-octanoylated serine residue characteristic of native ghrelin, yet it activates identical cellular signaling pathways. Laboratories utilizing Hexarelin in research peptides studies focus heavily on its precise molecular weight, conformational stability, and distinctive receptor cross-reactivity relative to larger polypeptide structures.
The primary biochemical pathway of Hexarelin involves potent agonism at the growth hormone secretagogue receptor type 1a (GHS-R1a), a seven-transmembrane G-protein coupled receptor (GPCR). Upon binding to GHS-R1a on somatotroph cell membranes, Hexarelin initiates a intracellular signal cascade mediated by Phospholipase C (PLC). This enzymatic activation hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
Subsequent IP3 mobilization triggers the rapid release of intracellular calcium ions ($Ca^{2+}$) from the endoplasmic reticulum into the cytosol. Elevated cytosolic calcium levels drive the exocytosis of stored somatotroph vesicles containing growth hormone. Preclinical studies suggest that this signaling cascade operates synergistically with endogenous growth hormone-releasing hormone (GHRH) pathways, providing an essential model for studying non-GHRH mediated endocrine stimulation in vitro.
In primary pituitary cell culture assays and rodent models, Hexarelin has demonstrated robust secretagogue activity. Investigators measure GH release kinetics following incubation with micro- to nanomolar concentrations of Hexarelin, noting a rapid concentration-dependent surge in somatotroph secretion. Data derived from preclinical literature indicate that Hexarelin exhibits higher peak amplitude GH responses in isolated pituitary tissue compared to earlier secretagogues.
Beyond baseline somatotroph stimulation, laboratory researchers examine how Hexarelin interacts with negative feedback loops governed by somatostatin (SS). In vitro data show that while somatostatin attenuates GHS-R1a downstream signaling, high-affinity binding by Hexarelin partially bypasses somatostatic inhibition, allowing continued cytosolic calcium transient generation. Researchers frequently reference our broader growth hormone secretagogue research hub to evaluate these cellular control mechanisms.
Uniquely within the growth hormone secretagogue class, Hexarelin binds with high affinity to the scavenger receptor CD36 (thrombospondin receptor) in addition to GHS-R1a. CD36 is abundantly expressed on cardiac myocytes, endothelial cells, and macrophages. Preclinical cardiac models—including isolated perfused heart preparations and rodent ischemia-reperfusion assays—utilize Hexarelin to explore CD36-mediated cell signaling.
In vitro models of cardiac ischemia indicate that Hexarelin activation of CD36 modulates fatty acid transport, oxidative stress signaling, and apoptotic cascades independent of GH release. Animal studies suggest that administration of Hexarelin prior to simulated ischemic insult reduces myocardial necrosis area and supports post-ischemic functional recovery. Consequently, Hexarelin serves as a dual-target research tool for investigating both endocrine and cardiovascular receptor networks.
When evaluating synthetic secretagogues for laboratory protocols, researchers frequently compare Hexarelin against structurally related compounds such as Ipamorelin, GHRP-6, and GHRP-2. While all four compounds target the GHS-R1a receptor, their selectivity profiles, receptor desensitization kinetics, and secondary hormone release characteristics vary significantly.
Hexarelin demonstrates the highest absolute peak GH release efficacy in vitro among these peptides, but it also induces rapid receptor desensitization (tachyphylaxis) upon repeated continuous exposure in receptor models. In contrast, Ipamorelin exhibits high selectivity for GHS-R1a without desensitizing the receptor or triggering secondary spikes in prolactin or cortisol. GHRP-6 and GHRP-2 show intermediate secretagogue potency, with GHRP-6 additionally influencing phospholipase-mediated appetite signaling pathways in hypothalamic models. Laboratories selecting compounds for long-term secretagogue signaling assays often analyze these comparative dynamics prior to protocol implementation.
Proper handling and reconstitution protocols are vital to maintain the structural integrity of lyophilized Hexarelin. For bench research, lyophilized vials should be reconstituted using sterile laboratory solvents such as bacteriostatic water (0.9% benzyl alcohol preserved) or sterile deionized water, depending on the requirements of the intended assay.
To solubilize the peptide without damaging its secondary structure, direct the solvent stream down the inner glass wall of the vial rather than forcefully onto the cake. Gentle swirling or smooth inversion should be employed until complete dissolution is achieved; aggressive vortexing must be avoided as mechanical shear stress can cause protein aggregation. Once reconstituted, stock solutions should be aliquoted into single-use polypropylene microtubes using aseptic laboratory technique to prevent repeated freeze-thaw cycles during experiment execution.
Lyophilized Hexarelin supplied by PX1 Research exhibits excellent long-term chemical stability when preserved under controlled environmental conditions. Unopened vials should be stored at -20°C or -80°C in a desiccated environment to prevent moisture absorption. Under sub-zero storage conditions, high-purity lyophilized hexapeptides remain stable for extended research timelines.
Following reconstitution, liquid solutions of Hexarelin should be kept refrigerated at 2°C to 8°C and used within a short research window if preserved with bacteriostatic water. For prolonged storage of reconstituted aliquots, solutions should be frozen at -80°C. Researchers must shield peptide solutions from direct ultraviolet light exposure, as tryptophan residues within the Hexarelin sequence (D-Trp and Trp) are susceptible to photo-oxidation over time.
Assay reproducibility depends directly on compound purity and lot-to-lot consistency. Low-purity peptide reagents containing synthesis side-products or truncated sequences yield erratic receptor binding data and skewed cellular assays. High-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS) are mandatory analytical tools for verifying Hexarelin quality.
PX1 Research enforces stringent analytical standards for all synthetic reagents. Every production lot undergoes third-party testing to confirm purity exceeding 98% via RP-HPLC, correct molecular mass matching sequence specifications via ESI-MS, and strict control over residual trifluoroacetic acid (TFA) salts. Furthermore, quantitative Limulus Amebocyte Lysate (LAL) testing guarantees low endotoxin thresholds, protecting sensitive cell culture models from bacterial pyrogen interference.
PX1 Research is dedicated to supporting North American research institutions, academic laboratories, and biotech entities with reference-grade biochemicals. Every batch of our Hexarelin product is USA-manufactured in compliance with ISO 9001 and ISO 17025 accredited quality management systems. Researchers can easily download batch-specific Certificate of Analysis (COA) documents directly from our platform.
To maintain chain of custody and minimize shelf degradation, orders are fulfilled directly from our temperature-controlled distribution hubs in California and Arizona. We offer same-day dispatch for orders confirmed Monday through Friday before cut-off times. Institutional buyers seeking volume pricing or customized analytical testing can explore our bulk lab supply program or browse our full catalog of specialized research peptides.
What is Hexarelin's primary receptor target in vitro?
Hexarelin acts primarily as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a). Additionally, preclinical assays show significant binding affinity for the CD36 scavenger receptor.
How does Hexarelin differ structurally from natural Ghrelin?
Natural ghrelin is a 28-amino-acid peptide requiring n-octanoylation at serine-3 for receptor activation. Hexarelin is a synthetic hexapeptide (6 amino acids) that activates GHS-R1a without requiring acylation.
Why is Hexarelin studied for cardiac tissue research alongside GHS-R1a?
Because Hexarelin binds to CD36 scavenger receptors expressed on cardiomyocytes, researchers utilize it to study signal transduction pathways involved in cardiac ischemia, apoptosis, and lipid transport independent of pituitary GH release.
What solvent is recommended for reconstituting Hexarelin in bench assays?
Bacteriostatic water (0.9% benzyl alcohol) is recommended for multi-use laboratory stock solutions stored at 2–8°C. For immediate cell culture applications sensitive to preservatives, sterile deionized water or phosphate-buffered saline (PBS) is preferred.
What purity level does PX1 Research guarantee for Hexarelin?
PX1 Research provides Hexarelin with a verified purity of ≥98% as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry analysis.
How does receptor desensitization present in Hexarelin research models?
Continuous or repeated exposure to Hexarelin in receptor assays leads to tachyphylaxis, characterized by down-regulation or desensitization of GHS-R1a intracellular calcium signaling over prolonged timelines.
Can Hexarelin solutions be subjected to multiple freeze-thaw cycles?
No. Repeated freeze-thaw cycles can cause peptide degradation and aggregation. Stock solutions should be divided into single-use aliquots prior to freezing at -80°C.
How are endotoxin levels verified for PX1 Research peptides?
Endotoxin levels are quantified using standardized Limulus Amebocyte Lysate (LAL) assays to ensure levels fall well within acceptable parameters for delicate cell culture and in vitro experiments.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.